Market Place
Sourcing Support
Oncorus liquidates a week after shedding workforce
12 Jun 2023 //
FIERCE BIOTECH
Facing bankruptcy, Oncorus lays off `substantially` all staff
02 Jun 2023 //
FIERCE BIOTECH
Oncorus Announces Workforce Reduction Plan
01 Jun 2023 //
GLOBENEWSWIRE
Oncorus Reports First Quarter 2023 Financial Results & Provides Business Updates
22 May 2023 //
GLOBENEWSWIRE
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
Oncorus to collaborate with Daewoong for Lipid Nanoparticle Formulations
04 Jan 2023 //
GLOBENEWSWIRE
Oncorus Announces Portfolio Reprioritization to IV-Administered, RNA Medicines
30 Nov 2022 //
GLOBENEWSWIRE
In cash saving mode, Oncorus cuts trial, staff, lease, and pipeline
30 Nov 2022 //
ENDPTS
Oncorus lays off 15% of workforce, drops solid tumor prospect
30 Nov 2022 //
FIERCEBIOTECH
Oncorus to Participate in Upcoming Investor Conferences
23 Nov 2022 //
GLOBENEWSWIRE
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector
18 Nov 2022 //
GLOBENEWSWIRE
Oncorus Announces Publication in Nature Communications Highlighting
07 Oct 2022 //
GLOBENEWSWIRE
Oncorus to Present at Chardan’s 6th Annual Genetic Medicines Conference
26 Sep 2022 //
GLOBENEWSWIRE
Oncorus to Present at the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Oncorus Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Oncorus Appoints Douglas Fambrough to Board of Directors
23 Jun 2022 //
GLOBENEWSWIRE
Oncorus to Present at the Jefferies Global Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Oncorus to Present at the H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
Oncorus Announces Appointment of Richard Wanstall as Chief Financial Officer
10 May 2022 //
GLOBENEWSWIRE
Oncorus Reports Q1 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Oncorus` Debt Capital Facility with K2 HealthVentures with $20M Fund at Closing
05 Apr 2022 //
GLOBENEWSWIRE
Oncorus to Present at the Maxim Group 2022 Virtual Growth Conference
21 Mar 2022 //
GLOBENEWSWIRE
Oncorus to Present at the Oppenheimer 32nd Annual Healthcare Conference
10 Mar 2022 //
GLOBENEWSWIRE
Oncorus Reports Q4 and FY 2021 Financial Results
09 Mar 2022 //
GLOBENEWSWIRE
Oncorus Announces Exclusive Licensing Agreement with Gaeta Therapeutics
11 Nov 2021 //
GLOBENEWSWIRE
Oncorus to Present Initial Data its Ongoing Ph1 Clinical Trial of ONCR-177
01 Oct 2021 //
GLOBENEWSWIRE
Oncorus Expands its Board with Appointment of Barbara Yanni
29 Jul 2021 //
GLOBENEWSWIRE
Oncorus to Host Investor Day and feature Lead Synthetic vRNA Product Candidates
15 Jun 2021 //
GLOBENEWSWIRE
Oncorus Announces Nomination of its First IV-Administered Viral RNA (vRNA)
27 May 2021 //
GLOBENEWSWIRE
Oncorus Reports First Q2021 Financial Results and Provides Business Highlights
04 May 2021 //
GLOBENEWSWIRE
Oncorus Announces Proposed Public Offering of Common Stock
09 Feb 2021 //
GLOBENEWSWIRE
Oncorus to Build GMP Viral Immunotherapy Mfg. Facility
04 Jan 2021 //
CONTRACTPHARMA
Oncorus plots early-stage plant in Boston area as it walks I-O candidate through
04 Jan 2021 //
ENDPTS
Oncorus prices 5.8M-share IPO at $15
02 Oct 2020 //
SEEKINGALFA
